Simplifying complexity in therapeutic protein drug development A symphony of antibodies to attack cancer Symphogen is a clinical-stage biopharmaceutical company near Copenhagen, Demark. Symphogen has a uniquely differentiated precision- medicine approach product pipeline based on monoclonal antibody (mAb) and mAb mixture drug candidates. In addition to development of individual mAb drug candidates, Symphogen is further pioneering the application of mAb mixtures as a differentiated approach to cancer therapy that can overcome some of the limitations of conventional single-target mAbs. A mAb mixture is a combination of two or more systematically selected, well-characterized mAbs developed as a single drug product. The mAbs in the mixture may bind different positions on the same tar

Join for free to read